Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Therapeutic cancer vaccines show limited efficacy as monotherapy due to self-tolerance and immunosuppressive tumor microenvironments.
• Combining cancer vaccines with systemic anticancer therapies (SACTs) is a promising strategy to improve treatment outcomes.
• Optimal timing and combinations of vaccines with chemotherapy and immune checkpoint inhibitors (ICIs) require further investigation.

Purpose of the Study:

• To review the immunogenicity of antiviral and anticancer vaccines when combined with SACTs, including chemotherapy and ICIs.
• To assess the impact of vaccine administration timing relative to SACT on immune responses.
• To evaluate the influence of steroids on vaccine immunogenicity.

Main Methods:

• Literature review of studies combining cancer vaccines with SACTs (chemotherapy, ICIs).
• Analysis of vaccine immunogenicity based on administration timing relative to SACT.
• Evaluation of the role of specific chemotherapeutic agents and steroids.

Main Results:

• Vaccine administration at nadir (15 days post-chemotherapy) enhances immunogenicity.
• Certain chemotherapies (e.g., low-dose metronomic cyclophosphamide, paclitaxel) can potentiate vaccine-induced T-cell responses.
• Concurrent administration of ICIs with cancer vaccines demonstrates synergistic effects compared to sequential approaches; steroids may reduce immunogenicity.

Conclusions:

• Vaccine timing relative to SACT is critical for maximizing immunogenicity.
• Specific chemotherapies and concurrent ICI use can enhance cancer vaccine efficacy.
• Further prospective trials are needed to optimize combination strategies and timing for improved therapeutic cancer vaccine outcomes.